NTLA Intellia Therapeutics, Inc.

Price Chart

Executive Summary

Intellia presented additional positive Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE at EAACI 2026, with the manuscript simultaneously published in NEJM. All key secondary endpoints were met with high statistical significance, including an 89% reduction in attacks requiring on-demand treatment and a 91% reduction in moderate/severe attacks. A rolling BLA submission was initiated in April, with regulatory approval and U.S. launch anticipated in H1 2027.

Actionable Insight

Key Facts

• Phase 3 HAELO trial met primary endpoint with 87% reduction in mean monthly attacks (p<0.0001) for lonvo-z vs placebo.
• 62% of lonvo-z patients were attack-free and therapy-free for the six-month efficacy evaluation period vs 11% placebo (p<0.0001).
• Key secondary endpoints: 89% reduction in attacks requiring on-demand treatment, 91% reduction in moderate/severe attacks, and -17.04 improvement in AE-QoL (all p<0.0001).
• No serious adverse events in the lonvo-z arm; all TEAEs were mild or moderate.
• Rolling BLA submission initiated with FDA in April 2026; regulatory approval and U.S. launch expected in H1 2027.
• Lonvo-z has Orphan Drug, RMAT, Innovation Passport, PRIME, and EU Orphan Drug designations.

Financial Impact

First-in-class in vivo CRISPR gene therapy for HAE with potential to transform treatment paradigm; peak sales could exceed $1B given HAE prevalence (1 in 50,000) and one-time curative profile. No financial figures provided in release.

Risk Factors

• FDA could issue a CRL on CMC or manufacturing grounds despite strong efficacy data.
• Commercial adoption may be slower than expected if payers impose restrictions on one-time gene therapy pricing.
• Competition from existing prophylactic therapies (Takhzyro, Haegarda, Orladeyo) with established market presence.

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status